Spire Healthcare Group (LON:SPI) Earns “Buy” Rating from Berenberg Bank

Berenberg Bank reaffirmed their buy rating on shares of Spire Healthcare Group (LON:SPI) in a report published on Tuesday, MarketBeat Ratings reports. The firm currently has a GBX 300 ($3.96) price objective on the stock.

Spire Healthcare Group Trading Up 0.2 %

Shares of SPI opened at GBX 235 ($3.10) on Tuesday. The stock has a fifty day moving average price of GBX 248.80 and a two-hundred day moving average price of GBX 245.27. The company has a debt-to-equity ratio of 169.51, a quick ratio of 0.74 and a current ratio of 0.70. The company has a market cap of £948.98 million, a price-to-earnings ratio of 3,357.14, a PEG ratio of 1.06 and a beta of 0.97. Spire Healthcare Group has a 52-week low of GBX 207 ($2.73) and a 52-week high of GBX 270.50 ($3.57).

Insider Buying and Selling

In related news, insider Justin Ash acquired 21,100 shares of the stock in a transaction on Tuesday, September 17th. The stock was purchased at an average price of GBX 236 ($3.12) per share, for a total transaction of £49,796 ($65,780.71). 34.71% of the stock is owned by corporate insiders.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.